Turner was diagnosed with Waldenström’s macroglobulinemia, which changes white blood cells into cancer cells and builds up in ...

He further explained he was diagnosed with a slow-growing "bone marrow cancer" called Waldenström's macroglobulinemia (WM): ...

What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...

The Pacers are also depleted, but they will have a key player for this matchup, their star center, Myles Turner. After being listed as questionable, Turner has been upgraded to available for this ...

The NHS’s top A&E doctor is urging the public to use 111 services this winter, as the health service launches its annual campaign with adverts across online video, radio, podcasts and social media.

Among them are normally innocuous statements such as, “Feel better soon” or “Wishing you a quick recovery,” the Kenyan ...

[6] The presented case shows that a late diagnosis of Turner's syndrome can make the choice of an optimal hormonal regimen even more difficult. Although the patient's final height was 0.4 cm ...

These findings were generally consistent across secondary clinical outcomes and across prespecified subgroups defined according to patient, pathogen, and syndrome characteristics.

This revealed a 45,X karyotype with no evidence of mosaicism, confirming the diagnosis of Turner's syndrome. The patient's height standard deviation scores (hSDS) were assessed according to a ...

Tampa General Hospital received a C grade for patient safety in five of its past six safety ratings after low scores for MRSA and blood infections. Despite assurances from officials that its grade ...

Pacers center Myles Turner has been ruled out of Monday's game against the Raptors in Toronto with a strained right calf after scoring 34 points and posting nine rebounds in Sunday's win over the ...

Neu­ro­gene has re­leased de­tails of an ad­verse event in a clin­i­cal tri­al test­ing its gene ther­a­py for Rett syn­drome, af­ter news of the safe­ty is­sue … ...